San Francisco biotech CytomX files for $100 million IPO

San Francisco-based biotech CytomX Theraputics has filed to raise $100 million for an initial public offering, a brief with the Securities and Exchange Commission shows . The company develops cancer immunotherapies that avoid healthy cells.